Fresh Off Being Acquired by Bruker, NanoString Scores Win in Patent Case

The German Federal Patent Court has ruled in favor of NanoString in a patent infringement case that has the company pitted against 10X Genomics.

Omar Ford

May 7, 2024

1 Min Read
Image Credit: Peter Dazeley via Getty Images

NanoString, which has been acquired by Bruker, has won a victory in a patent battle with 10x Genomics.  Billerica, MA-based Bruker said that the German Federal Patent Court has ruled in favor of NanoString Technologies by invalidating European Patent No. 2794928B1 (the “928 Patent”) in Germany (case 3 Ni 20/22).

Bruker said NanoString will now seek an end to the injunction impacting sales of CosMx SMI products in Germany.

The 928 Patent has been asserted by 10x Genomics against NanoString in patent infringement cases in Germany and before the European Unified Patent Court (UPC) involving NanoString’s CosMx Spatial Molecular Imager (SMI) products for RNA detection. The Federal Patent Court ruled that the German part of the 928 Patent is invalid.

“NanoString has consistently maintained that the patents being asserted by 10x Genomics against NanoString’s CosMx SMI products are invalid. Today’s ruling of the German Federal Patent Court is a decisive victory for NanoString and Bruker and a resounding vindication of NanoString’s belief from the outset that these cases are without merit. This ruling is also a win for science and enables a re-leveling of the playing field in the research tools industry in Germany,” said Mark R. Munch, President of the Bruker NANO Group.

Related:NanoString's Assets to be Acquired by Bruker

As of press time, 10X Genomics could not be reached for comment.

About three months ago, NanoString filed for bankruptcy – weary from paying $31 million to 10X Genomics after losing a patent infringement lawsuit

About the Author(s)

Omar Ford

Omar Ford is MD+DI's Editor-in-Chief. You can reach him at [email protected].


Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like